TA Science announced that it will use Geron's license to develop and market non-therapeutic products using Geron's small molecule telomerase activators.
The compound is derived from a Chinese herb(Astragalus), and activates telomerase genes in human cells. Human studies have been underway since 2005.
http://www.lef.org/n...6&Section=AGING
New Product Scientifically Battles Aging at the Cellular Level-Exclusively licensed from the Geron Corporation, TA-65 is the world's first Telomerase Activator
PR Newswire
04-09-07
NEW YORK, April 9, 2007 /PRNewswire via COMTEX/ -- Telomerase Activation Sciences, Inc. (TA Sciences) announced on March 12 its license with Geron to develop and market non-therapeutic products using Geron's small molecule telomerase activators. Now TA Sciences announces the opening of the TA Sciences Center in Manhattan where customers can purchase TA Sciences' first product, a nutraceutical containing the telomerase activating agent "TA-65."
"TA Sciences welcomes our first customers and the launch of the world's first telomerase activator product," said Noel Thomas Patton, founder of TA Sciences. "A natural consequence of aging is the shortening of telomeres (caps of DNA located at the ends of all chromosomes), which ultimately results in loss of cell function. TA-65 offers the potential of reducing or reversing telomere shortening and battles tissue and organ degeneration by rejuvenating aging cells."
TA-65 is the result of vigorous scientific research that began at Geron in 1992. Already the response from the scientific community to the news of TA Sciences' ground-breaking launch has been very enthusiastic: "Telomerase Activation is the single most promising approach to reversing the effects of aging," said Michael Fossel, MD, PhD., Clinical Professor of Medicine at Michigan State University, author, and recognized authority on aging and age- related clinical disease.
And Dr. William H. Andrews, founder of Sierra Sciences, LLC and one of the principal discoverers of the telomerase genes, said: "Cleopatra, Ponce de Leon, and untold others throughout the ages have searched for the secrets of youth. That search has been futile, until now: Telomerase Activation is the first and only scientifically sound way to approach anti- aging. TA-65 is the first product in history that has been proven to slow or reverse cellular aging. Congratulations to TA Sciences and Geron!"
On April 30, 2007 TA Sciences plans to publish the results of the Pivotal 2005 Anti-Aging Trial, which is the first ever human clinical trial of a telomerase activator. This trial shows statistical verification of the anti- aging benefits of telomerase activation.
The TA Sciences Center is located at 24 E. 64th Street in New York. The company offers its telomerase-activating products as part of the 12 month "Patton Protocol." The driver of TA Sciences' product line is the telomerase- activating small molecule "TA-65," sold under license from Geron. For more information on TA Sciences visit http://www.TASciences.com or call 888-360-8886. For more information on Geron visit http://www.Geron.com.
SOURCE TA Sciences Inc.
CONTACT: Greta Blackburn of TA Sciences Inc., cell, +1-818-634-5941
URL: http://www.tasciences.com
http://www.Geron.com
http://www.prnewswire.com www.prnewswire.com
Here is the full report of the 2005 study (I believe that I read somewhere that there is additional information that will be revealed from the study on the 30th of April).
http://www.tascience...m/ta/blum2.html
The Pivotal 2005 Anti-Aging Trial of TA-65 was a double blind, placebo controlled, 24 week study in which subjects consumed 2 or 4 tablets daily of a placebo control substance (placebo groups) for 12 weeks or 2 or 4 tablets daily of a TA-65 precursor molecule (TA-41) for 12 weeks (product groups). The product tablets each contained 10 mg of TA-41 (an Astragalus extract) along with other botanical extracts and excipients.
The placebo control tablets were essentially indistinguishable from the product tablets in appearance and taste, even when the tablet was broken. The 12 week placebo or product use period was followed by a further 12 week follow-up period. To ascertain active substance in the blood (for compliance and to better understand the relationship between TA-41 and TA-65), analytical measurements of TA-41 and TA-65 (the presumed major metabolite of TA-41) were conducted at 6 weeks and 12 weeks.
Thirty six male subjects aged 60-85 who expressed an interest in reducing the signs and symptoms of aging and who reported a gradual decline in overall energy levels at the screening visit were recruited. Subjects were randomly assigned to the placebo group (n=6 taking two placebo tablets, one in the morning, one in the evening; n=6 taking 4 placebo tablets, two in the morning, two in the evening) or the product treatment group (n=12 taking two product tablets, one in morning, one in evening; n=12 taking 4 product tablets, 2 in morning, 2 in evening). Subjects were assessed at baseline and at 6 weeks, 12 weeks and 24 weeks from the first dose of product. The full study design is described in Appendix A.
Here is a paper with evidence saying telomerase is not an oncogene:
http://www.nature.co...l/1205076a.html
There is a thread on this topic in supplements, but where as it is particularly relevant to conversations occurring here in SENS, I thought that I would open this up for discussion.